This article was published in CIDRAP 16 January 2020. A report by Chris Dall.
The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released today.